MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 125 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q2 2014. The put-call ratio across all filers is 0.57 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $195,000 | +343.2% | 142,361 | +888.6% | 0.04% | +311.1% |
| Q1 2017 | $44,000 | -36.2% | 14,400 | -14.3% | 0.01% | -40.0% |
| Q4 2016 | $69,000 | -36.1% | 16,800 | -1.2% | 0.02% | -37.5% |
| Q3 2016 | $108,000 | +9.1% | 17,000 | -7.1% | 0.02% | +9.1% |
| Q2 2016 | $99,000 | -36.5% | 18,300 | -1.6% | 0.02% | -35.3% |
| Q1 2016 | $156,000 | +6.1% | 18,600 | -0.3% | 0.03% | +3.0% |
| Q4 2015 | $147,000 | -16.5% | 18,650 | -9.7% | 0.03% | -17.5% |
| Q3 2015 | $176,000 | -30.2% | 20,650 | +1.2% | 0.04% | -18.4% |
| Q2 2015 | $252,000 | +4.1% | 20,400 | 0.0% | 0.05% | +4.3% |
| Q1 2015 | $242,000 | +4.8% | 20,400 | 0.0% | 0.05% | 0.0% |
| Q4 2014 | $231,000 | +26.9% | 20,400 | -1.4% | 0.05% | +17.5% |
| Q3 2014 | $182,000 | +24.7% | 20,700 | +3.5% | 0.04% | +29.0% |
| Q2 2014 | $146,000 | – | 20,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 5,000,000 | $20,400,000 | 4.19% |
| Consonance Capital Management LP | 9,067,998 | $36,997,000 | 4.06% |
| Lagoda Investment Management, L.P. | 1,522,529 | $6,212,000 | 2.13% |
| INDUS CAPITAL PARTNERS, LLC | 1,050,000 | $4,284,000 | 0.56% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 9,072,877 | $37,017,000 | 0.32% |
| GARRISON BRADFORD & ASSOCIATES INC | 77,700 | $317,000 | 0.29% |
| Cannell & Co. | 1,572,978 | $6,418,000 | 0.23% |
| Virtus ETF Advisers LLC | 179,625 | $733,000 | 0.22% |
| LeJeune Puetz Investment Counsel LLC | 3,976 | $161,000 | 0.12% |
| STONERIDGE INVESTMENT PARTNERS LLC | 221,838 | $905,000 | 0.12% |